| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide new methods for treating disorders in which TNFα activity is detrimental. <P>SOLUTION: The methods for treating disorders in which TFNα activity is detrimental includes biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα). The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K<SB POS="POST">d</SB>=10<SP POS="POST">-8</SP>M or less), a slow off rate for hTNFα dissociation (e.g., K<SB POS="POST">off</SB>=10<SP POS="POST">-3</SP>sec<SP POS="POST">-1</SP>or less) and neutralize hTNFα activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. <P>COPYRIGHT: (C)2013,JPO&INPIT |
